Faster global financial news!
AI company Owkin signs drug discovery deal with Germany's Boehringer Ingelheim for cancer and immunology drugs
The agreement grants Boehringer Ingelheim access to Owkin's AI research platform and patient data to accelerate the development of treatments. This deal builds on a pilot project conducted by the companies in 2025. Financial terms were not disclosed.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
NVIDIA RTX Spark Laptops Launch Globally, Featuring Blackwell RTX Graphics, Starting at $2,399
-
2
CCT Token (Carbon Credit Token) Status Analysis and Trading Channels
-
3
IMX Token: Analysis of the ImmutableX Ecosystem, Token Value, and Long-Term Development Potential
-
4
TRON's Q3 Stablecoin Settlement Volume Reaches $2.2 Trillion, TRX Supply Grows for 108 Consecutive Days
-
5
ETH inter-exchange price spread reaches 1.06%.
-
6
Cryptocurrency Trading Platforms and Blockchain Technology Platforms Analysis
-
7
Verge (XVG) Privacy Coin: Current Status and Long-Term Value Analysis
-
8
Galxe (G) Token Analysis: From Web3 Credential Network to Gravity L1 Mainnet
-
9
A Review of Mainstream Cryptocurrency Exchanges and Their Features in 2026
-
10
What is Chia Network (XCH)? Current Status and Technical Analysis
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
